Editorial Comment: LDL-C Reduction After CABG With Low-Dose Statin Therapy: Implications for Secondary Prevention
Abstract
Coronary artery bypass grafting (CABG) is an established revascularization procedure for patients with advanced coronary artery disease. However, surgical revascularization does not eliminate the underlying atherosclerotic process or the risk of subsequent cardiovascular events. Effective lipid-lowering therapy therefore remains a cornerstone of long-term secondary prevention following CABG. In this issue, Agha and colleagues report longitudinal changes in low-density lipoprotein cholesterol (LDL-C) among 170 patients prescribed a 20 mg statin regimen following CABG [1]. Their findings highlight an important clinical concern regarding the adequacy of LDL-C reduction and the appropriate timing of therapeutic reassessment and intensification. The study demonstrated a progressive increase in median LDL-C reduction, from 16.3% at three months to 31.0% at six months and 45.9% at 12 months. Notably, none of the patients achieved an LDL-C reduction of at least 50% at three or six months, while only 49 patients (28.8%) reached this threshold at 12 months. Mean LDL-C decreased from 152.9 mg/dL at baseline to 94.7 mg/dL after one year [1]. Although these findings indicate substantial improvement in lipid parameters, the majority of patients did not achieve the study-defined reduction threshold. Furthermore, the mean LDL-C concentration at 12 months remained considerably above the recommended target of less than 55 mg/dL for very-high-risk patients, as emphasized in the 2024 European Association for Cardio-Thoracic Surgery (EACTS) guidelines [2]. These observations raise concerns regarding the adequacy of lipid management during the first postoperative year. An important strength of the study is its longitudinal assessment of LDL-C at predefined intervals, allowing evaluation of lipid changes over time. Nevertheless, several methodological considerations warrant attention. The intervals between lipid measurements limit the ability to determine precisely when individual patients achieved specific LDL-C reductions. Moreover, restricting the analysis to patients with complete lipid profiles may introduce selection bias, as individuals maintaining regular follow-up could differ systematically from those with incomplete records. Such differences may influence treatment adherence, clinical outcomes, and the generalizability of the findings to the broader CABG population. The designation of the treatment regimen as "low-dose statin therapy" also requires careful interpretation. Statin intensity is determined by the specific medication and its prescribed dosage rather than the dose in milligrams alone. Consequently, a 20 mg regimen cannot be classified reliably without identifying the statin administered. Furthermore, the absence of a comparison group receiving alternative statin intensities limits conclusions regarding the relative effectiveness of different lipid-lowering strategies. Treatment adherence, medication adjustments, baseline cardiovascular risk, and other potentially influential clinical factors were not adequately characterized. Accordingly, the findings should be interpreted primarily as evidence of suboptimal LDL-C goal attainment within the studied cohort rather than definitive evidence that a particular statin dose caused an inadequate therapeutic response [1]. From a clinical perspective, these findings emphasize the importance of early lipid reassessment and individualized treatment optimization following CABG. Contemporary recommendations support intensive or maximally tolerated statin therapy for secondary prevention, with the addition of nonstatin lipid-lowering agents, including ezetimibe, when LDL-C remains above the recommended threshold. Further treatment intensification may be appropriate for patients who continue to demonstrate inadequate lipid control despite optimized therapy [2,3]. The 2023 American Heart Association/American College of Cardiology multisociety guideline for chronic coronary disease recommends reassessment of lipid levels approximately 4–12 weeks after initiation or adjustment of lipid-lowering therapy [4]. Such monitoring provides an opportunity to evaluate medication adherence, tolerability, treatment response, and the need for therapeutic modification before prolonged exposure to elevated LDL-C occurs. The clinical significance of effective lipid management extends beyond systemic cardiovascular risk reduction to the preservation of bypass graft integrity. The landmark Post Coronary Artery Bypass Graft Trial demonstrated that more intensive LDL-C lowering was associated with reduced progression of atherosclerotic disease in saphenous vein bypass grafts compared with more moderate lipid lowering [5]. Although Agha and colleagues did not investigate graft patency or graft-related cardiovascular events, their findings reinforce the importance of sustained lipid management as an essential component of comprehensive postoperative care. Achieving appropriate LDL-C targets may therefore contribute to broader secondary prevention objectives, although the present study cannot establish a direct relationship between the observed lipid reductions and subsequent graft outcomes. It is equally important to distinguish improvements in surrogate biochemical markers from demonstrated clinical benefits. LDL-C reduction was the principal outcome evaluated in the study, whereas myocardial infarction, graft failure, repeat revascularization, cardiovascular mortality, and all-cause mortality were not assessed. Consequently, the observed lipid changes should not be interpreted as direct evidence of improved clinical outcomes within this cohort. Nevertheless, the findings identify a potentially important gap between lipid-lowering treatment and guideline-recommended therapeutic goals, highlighting opportunities for more structured postoperative lipid monitoring and treatment optimization. In conclusion, the study by Agha and colleagues provides valuable observational evidence regarding LDL-C reduction during the first year following CABG. Despite progressive improvement in lipid concentrations, a substantial proportion of patients did not achieve the desired percentage reduction, and the average LDL-C level remained above contemporary secondary prevention targets. These findings underscore the importance of assessing lipid-lowering efficacy not merely by the presence of improvement but by the achievement of individualized, guideline-directed treatment goals. Early reassessment, evaluation of adherence and tolerability, and timely intensification of lipid-lowering therapy when indicated should remain integral components of post-CABG management. Future prospective investigations incorporating medication adherence, statin intensity, adjunctive lipid-lowering therapies, and clinically meaningful cardiovascular outcomes would further clarify strategies for optimizing long-term secondary prevention in this high-risk population [1,4]. References Agha F, Aziz NI, Khan Z, Siddiqui MI, Sarhandi MN, Khan MQA. Proportion and magnitude of LDL-C reduction following CABG with low-dose statin therapy: a retrospective cohort study. Pak Heart J. 2026;59(5):1582-1588. DOI: 10.47144/phj.v59i5.3322 Jeppsson A, Rocca B, Hansson EC, Gudbjartsson T, James S, Kaski JC, et al. 2024 EACTS guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg. 2025;67(1):ezae355. DOI: 10.1093/ejcts/ezae355 Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-418. DOI: 10.1016/j.jacc.2022.07.006 Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-119. DOI: 10.1161/CIR.0000000000001168 Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336(3):153-62. DOI: 10.1056/NEJM199701163360301